Wells Fargo’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Wells Fargo’s Portfolio MBVX Stock Details MBVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1	Closed	–	–	6730
2017 Q4	$0	Hold	1	–	–	﹤0.01%	6688
2017 Q3	$0	Hold	1	–	–	﹤0.01%	6611
2017 Q2	$0	Hold	1	–	–	﹤0.01%	6626
2017 Q1	$0	Buy	+1	New	+$9	﹤0.01%	6666

Other funds holding MBVX

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Wells Fargo's MBVX Position: Q1 2018 in Review

Wells Fargo sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q1 2018, closing a stake of 1 share.

Wells Fargo first reported a position in MBVX in Q1 2017 and held it in 4 quarters. The position peaked at $0 in Q4 2017. 11 funds tracked by Wall St. Rank hold MBVX as of Q1 2018.

Wells Fargo reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q1 2018 after selling out during the quarter.
Wells Fargo sold 1 MABVAX THERAPEUTICS HLDGS INC share in Q1 2018.
Wells Fargo first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q1 2017 and held it in 4 quarters.
Wells Fargo's MABVAX THERAPEUTICS HLDGS INC position peaked at $0 in Q4 2017.
11 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q1 2018.

Based on Wells Fargo's 13F filing for Q1 2018, filed 2 May 2018.